Evidence map›Paper›PMID 41131545›Full record

ArticleBreast cancer research : BCR2025

Modulating phosphodiesterase-5 activity to suppress the immunosuppressive mechanisms of myeloid-derived suppressor cells in breast cancer.

Yingxue Guo, Mengyun Chen, Qi Yuan, Jie Huang, Wen Mao, Xianli Liu, Lu Jin, Lijia Chen, Jingyi Lou, Xia Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yingxue Guo *The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Jinhua Academy, Hangzhou, 310053, Zhejiang, China.
Mengyun Chen *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Qi Yuan *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Jie HuangThe First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310053, Zhejiang, China.
Wen MaoTaizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, 317000, Zhejiang, China.
Xianli LiuThe First Hospital of Jiaxing, Jiaxing, 314000, Zhejiang, China.
Lu JinThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Jinhua Academy, Hangzhou, 310053, Zhejiang, China.
Lijia ChenSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Jingyi LouSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Xia LiuThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Jinhua Academy, Hangzhou, 310053, Zhejiang, China.
Qi PanWenling TCM Hospital Affiliated to Zhejiang Chinese Medical University, Wenling, 317500, Zhejiang, China. wlpanqi@163.com.
Huiying FuThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Jinhua Academy, Hangzhou, 310053, Zhejiang, China. fhy131@126.com.
Qiyang ShouThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Jinhua Academy, Hangzhou, 310053, Zhejiang, China. sqy133@126.com.

Funding

National Natural Science Foundation of China 82274175, 82174026, 82474168, 82404915Natural Science Foundation of Zhejiang Province LY24H160017, LQ23H280007, LY23H280009
6 · The paper itself

Abstract

Phosphodiesterase-5 (PDE5) inhibitors have been shown to have potential as an adjuvant therapy for cancer. Tadalafil is a potent and selective PDE5 inhibitor that has been shown to inhibit the aggregation of myeloid-derived suppressor cells (MDSC) within tumors. Given the pivotal role of STAT3 signaling in mediating MDSC immunosuppression, we investigated the impact of tadalafil on MDSC differentiation and inhibitory function. Our findings indicate that tadalafil significantly attenuates in situ breast tumor growth and metastasis while impairing the capacity of MDSCs to suppress T-cell proliferation, concomitant with reduced STAT3 phosphorylation. Transcriptomic analysis revealed that tadalafil modulates MDSC metabolism, upregulates NAD

Indexed as

Breast NeoplasmsCyclic Nucleotide Phosphodiesterases, Type 5Myeloid-Derived Suppressor CellsPhosphodiesterase 5 InhibitorsTadalafilAnimalsCell DifferentiationCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMicePoly (ADP-Ribose) Polymerase-1Signal TransductionCyclic Nucleotide Phosphodiesterases, Type 5PARP1 protein, humanPhosphodiesterase 5 InhibitorsPoly (ADP-Ribose) Polymerase-1STAT3 protein, humanSTAT3 Transcription FactorTadalafilBreast cancerImmunosuppressionMyeloid-derived suppressor cellsPhosphodiesterase type 5 inhibitorTumor microenvironment

Identifiers

PMID41131545
PMCPMC12551186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.